Ventas globales del mercado farmaceutico - Octubre 2010

U.S.A. $223.5 billion up 4%

CANADA $19.2 billion up 4%

EUROPE (TOP 5) $107.6 billion up 2%

GERMANY $35.1 billion up 4%

FRANCE $28.3 billion up 0%

ITALY $16.0 billion up 0%

SPAIN $14.6 billion up 1%

UK $13.6 billion up 2%

JAPAN (including hospitals) $84.1 billion up 1%

CHINA (hospital) $31.1 billion up 23%

LATIN AMERICA (TOP 4) $34.3 billion

BRAZIL $16.9 billion up 20%

MEXICO $7.6 billion up 1%

VENEZUELA $6.0 billion up 28%

ARGENTINA $3.8 billion up 24%

AUSTRALIA/NZ $9.4 billion up 6%

The top 5 therapy classes at ATC3 level in the 12 months to October 2010 were:

1. C10A – Cholesterol & trigly. regulators

2. A2B - Antiulcerants

3. N5A - Antipsychotics

4. N6A – Antidepressants & mood stabilisers

5. C9C – Angioten-II Antag, Plain

The top 5 products in the 12 months to October 2010 were:

1. Lipitor

2. Plavix

3. Nexium

4. Seretide

5. Crestor

The top 5 corporations in the 12 months to October 2010 were:

1. Pfizer

2. Novartis

3. AstraZeneca

4. Merck & Co

5. GlaxoSmithKline

Source: IMS

Sales Through Retail Pharmacies (Twelve months to October 2010)*

NORTH AMERICA $242.7 billion up 4%